Dicerna Pharma has enticed another big pharma to partner its RNA interference platform, attracting a $200 million upfront deal with Roche for a drug to treat hepatitis B virus infections.

Explore seven biotech companies advancing clinical drugs in the race for regulatory approval to revolutionize hepatitis B ...

A three-drug combination worked better than any of them alone in treating ALS caused by mutations in the SOD1 gene, per a new ...

Liver fibrosis is a key process in the progression of chronic liver diseases. However, there are currently no drugs ...

Liver fibrosis is a key process in the progression of chronic liver diseases. However, there are currently no drugs ...

Functional cure, defined as durable hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA titers below the ...

The U.S. capacity to battle hepatitis B and C has been leveled a devastating blow with the recent closure of the CDC’s ...

Uncover what drives alcoholic hepatitis, how it’s detected, and why stopping alcohol is vital for better health and recovery.

A Mumbai-based doctor has reported that a young woman contracted hepatitis B after a threading procedure at a salon, ...